GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates
Business Wire•29/09/2026•18:37 ET
0
Key Highlights
- ➤€6.5 million collected from paid early access programs in H1 2026
- ➤Reported IFRS revenue €(1.2) million after €3.4 million rebates and €4.3 million estimate change
- ➤Net cash used in operating activities fell 37% to €1.6 million
- ➤Catalent technology transfer completed; new GMP batch manufacturing started
- ➤RECOVER Phase III trial targeted for H2 2027, subject to financing
Expert Statements
Jan Eryk Umiastowski, Chief Financial Officer of GenSight Biologics
“The first half of 2026 marked a turning point for GenSight: for the first time since 2022, patients received GS010/LUMEVOQ(®) under authorized paid early access programs, and as a result, we collected €6.5 million over the period.”
Jan Eryk Umiastowski, Chief Financial Officer of GenSight Biologics
“The negative revenue reported for the first half reflects future rebates and a one-off non-cash change in accounting estimate and so does not capture the stronger cash collection the company actually achieved.”
Jan Eryk Umiastowski, Chief Financial Officer of GenSight Biologics
“Early access revenues enabled us to reduce our operating cash burn by 37% to €1.6 million in the first half.”
Jan Eryk Umiastowski, Chief Financial Officer of GenSight Biologics
“With the successful transfer of our manufacturing process to Catalent, our priority now is to secure the structural financing for the RECOVER Phase III trial.”
GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates
* €6.5 million collected from paid early access programs; after recognition of rebates and a €4.3 million non-cash change in accounting estimate, reported IFRS revenue amounted to €(1.2) million.
Get started
Create a free account to read the full story.